AVIR - CIK 0001593899
The table below shows Atea Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$132.03M | -$135.50M | -$85.39M | -$120.98M | -$87.00M | $296.73M |
| Capital expenditure | - | - | - | $1.94M | $4.00K | $26.00K |
| Investing cash flow | $188.79M | $56.10M | $40.30M | -$455.41M | -$4.00K | -$26.00K |
| Dividends paid | - | - | - | - | - |
Atea Pharmaceuticals, Inc. reported operating cash flow of -$132.03M for fiscal year 2025. That is up 2.6% from -$135.50M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$7.91M (FY 2018) to -$132.03M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $25.52M | $0.00 | - | - | - | - |
| Financing cash flow | -$25.75M | $267.00K | $257.00K | $370.00K | $1.47M | $531.75M |